Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$31.49
$31.46
$19.05
▼
$32.56
$3.86B0.742.62 million shsN/A
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$42.43
-1.0%		$37.31
$25.52
▼
$43.49
$2.47B0.93834,570 shs115,400 shs
Novavax, Inc. stock logo
NVAX
Novavax
$10.02
-2.9%		$8.53
$6.20
▼
$11.97
$1.66B2.454.70 million shs565,386 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
0.00%0.00%0.00%+0.64%+53.31%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
+3.90%+8.07%+20.39%+30.04%+15.53%
Novavax, Inc. stock logo
NVAX
Novavax
+1.98%+12.05%+39.27%+1.28%+36.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$31.49
$31.46
$19.05
▼
$32.56
$3.86B0.742.62 million shsN/A
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$42.43
-1.0%		$37.31
$25.52
▼
$43.49
$2.47B0.93834,570 shs115,400 shs
Novavax, Inc. stock logo
NVAX
Novavax
$10.02
-2.9%		$8.53
$6.20
▼
$11.97
$1.66B2.454.70 million shs565,386 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
0.00%0.00%0.00%+0.64%+53.31%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
+3.90%+8.07%+20.39%+30.04%+15.53%
Novavax, Inc. stock logo
NVAX
Novavax
+1.98%+12.05%+39.27%+1.28%+36.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
2.56
Moderate Buy$32.001.62% Upside
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
2.36
Hold$47.1111.02% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.33
Hold$14.0039.66% Upside

Current Analyst Ratings Breakdown

Latest CPRX, HRMY, and NVAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/26/2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$60.00
8/17/2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
8/11/2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/6/2026
Novavax, Inc. stock logo
NVAX
Novavax
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/5/2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold$39.00
8/5/2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$29.00 ➝ $34.00
8/5/2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$37.00
8/4/2026
Novavax, Inc. stock logo
NVAX
Novavax
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
8/4/2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$70.00
8/4/2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $50.00
7/31/2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$50.00 ➝ $51.00
(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$596.96M6.46$2.92 per share10.77$7.76 per share4.06
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$868.45M2.85$3.27 per share12.97$17.16 per share2.47
Novavax, Inc. stock logo
NVAX
Novavax
$413.80M4.00$3.48 per share2.88($1.16) per share-8.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$214.33M$1.7418.1010.220.9637.08%35.76%31.31%N/A
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$158.69M$3.0813.8010.660.3818.88%20.06%14.15%11/3/2026 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
$440.30M-$1.52N/AN/AN/A-59.87%-14.82%-13.35%11/5/2026 (Estimated)

Latest CPRX, HRMY, and NVAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Novavax, Inc. stock logo
NVAX
Novavax
-$0.3798-$0.32+$0.0598-$0.32$52.51 million$56.70 million
8/4/2026Q2 2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$0.9560$1.28+$0.3240$1.28$250.77 million$261.28 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/AN/AN/AN/AN/A
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/A
7.10
6.84
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
0.13
3.48
3.45
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.33
2.30

Institutional Ownership

CompanyInstitutional Ownership
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
79.22%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
86.23%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
10.40%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
11.00%
Novavax, Inc. stock logo
NVAX
Novavax
1.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
80122.42 million109.69 millionOptionable
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
20058.24 million51.83 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990164.95 million162.31 millionOptionable

Recent News About These Companies

Novavax to Participate in September Investor Conferences
September 2 at 7:14 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novavax-participate-september-investor-conferences-210000338.html
Novavax to Participate in September Investor Conferences
September 2 at 5:00 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/novavax-to-participate-in-september-investor-conferences-302867780.html
Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor
September 2 at 9:30 AM  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/09/61573251/novavax-stock-rises-despite-no-confirmed-news-behind-the-matrix-m-rumor
What's going on with Novavax stock?
September 1 at 6:10 PM  |  msn.comhttps://www.msn.com/en-us/news/other/what-s-going-on-with-novavax-stock/ar-AA2bmfh9
Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?
September 1 at 1:31 PM  |  247wallst.comhttps://247wallst.com/investing/2026/09/01/novavax-jumps-6-on-matrix-m-oncology-speculation-is-the-royalty-model-the-real-story/
Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?
September 1 at 1:12 PM  |  247wallst.comhttps://247wallst.com/investing/2026/09/01/novavax-jumps-6-on-matrix-m-oncology-speculation-is-the-royalty-model-the-real-story/?utm_source=snapi
What's Going On With Novavax Stock?
September 1 at 1:11 PM  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/09/61555730/whats-going-on-with-novavax-stock-2
Novavax (NASDAQ:NVAX) Shares Up 5.3% - Here's What Happened
August 31 at 12:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-novavax-nasdaq-nvax-shares-up-53-heres-what-happened-2026-08-31/
Novavax Stock Climbs Monday: What's Going On?
August 31 at 12:00 PM  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/08/61526631/novavax-stock-climbs-monday-whats-going-on
Research Analysts Set Expectations for Novavax Q3 Earnings
August 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30991307
How Expanded Nuvaxovid Royalties and Partner-led Execution Could Shape Novavax’s (NVAX) Investment Narrative
August 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/expanded-nuvaxovid-royalties-partner-led-190520474.html
Has Novavax (NVAX) Fallen Far Enough To Look Cheap?
August 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novavax-nvax-fallen-far-enough-130622971.html
Novavax (NVDA) Following Updated Nuvaxovid Approval Faces A Wide Fair Value Debate
August 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novavax-nvda-following-updated-nuvaxovid-170451700.html
Novavax's Nuvaxovid Approved in US, EU, Japan for 2026-2027 Season
August 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novavax-apos-nuvaxovid-approved-us-130419318.html
NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open
August 28, 2026  |  stocktwits.comS
Novavax's XFG-Adapted Nuvaxovid Approved In U.S., EU, Japan For 2026-2027 Season
August 28, 2026  |  rttnews.comhttps://www.rttnews.com/3686496/novavax-s-xfg-adapted-nuvaxovid-approved-in-u-s-eu-japan-for-2026-2027-season.aspx
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
August 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novavaxs-partnership-strategy-continues-deliver-123000950.html
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
August 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/novavaxs-partnership-strategy-continues-to-deliver-with-xfg-adapted-nuvaxovid-approvals-in-the-us-eu-and-japan-for-2026-2027-vaccination-season-302862775.html
Zacks Research Has Negative Outlook for Novavax Q3 Earnings
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-zacks-research-has-negative-outlook-for-novavax-q3-earnings-2026-08-28/
QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax
August 27, 2026  |  benzinga.comhttps://www.benzinga.com/markets/biotech/26/08/61484141/quick-spark-fda-approves-updated-covid-vaccines-from-moderna-pfizer-novavax
US FDA approves updated COVID vaccines for 2026-27 season
August 27, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-updated-covid-vaccines-2026-27-season-2026-08-27/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Catalyst Pharmaceuticals stock logo

Catalyst Pharmaceuticals NASDAQ:CPRX

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Harmony Biosciences stock logo

Harmony Biosciences NASDAQ:HRMY

$42.43 -0.43 (-0.99%)
As of 10:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Novavax stock logo

Novavax NASDAQ:NVAX

$10.02 -0.30 (-2.87%)
As of 10:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas